BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

LungRx Inc. (UTHR) TRIUMPH Trial Enrollment to Close


7/11/2007 9:48:43 AM

SILVER SPRING, Md., July 11 /PRNewswire-FirstCall/ -- Lung Rx, Inc., a wholly-owned subsidiary of United Therapeutics Corporation , announced today that patient enrollment in its TRIUMPH (TReprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension) registration trial will close on July 13, 2007.

The company's enrollment target is for 200 patients to complete the 12- week study, net the number of patients who discontinue the study prior to completion. As of July 10, 2007, approximately 232 patients were enrolled in the TRIUMPH study and approximately 15 patients did not complete the 12-week study period.

"We are excited to achieve this important milestone," said Martine Rothblatt, Ph.D., Chairman and CEO of Lung Rx and United Therapeutics. "I am proud of the clinical development team, including all of the investigators who have participated in TRIUMPH. In particular, we owe a tremendous debt of gratitude to the Co-Chairmen of our Steering Committee, Dr. Lewis Rubin and Dr. Werner Seeger, and to our Vice-Chairman, Dr. Horst Olschewski, for shepherding TRIUMPH to this milestone."

TRIUMPH is a 12-week, multi-center, double-blind, randomized, placebo- controlled study of inhaled treprostinil in NYHA Class III and IV patients with severe PAH.

Lung Rx is a biotechnology company focused on unmet medical needs in pulmonary medicine and pulmonary delivery of innovative therapeutic products.

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products for patients with chronic and life- threatening cardiovascular, cancer and infectious diseases.

United Therapeutics Corporation

CONTACT: Andrew Fisher of United Therapeutics Corporation,+1-202-483-7000, Afisher@unither.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES